Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PulmoBind
- Development stage
- Phase 2
- Lead developer
- Montréal Heart Institute
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
PulmoBind (DFH-12) is a radiopharmaceutical imaging agent developed by the Montréal Heart Institute for the non-invasive detection and evaluation of pulmonary hypertension. As a small molecule agonist of the adrenomedullin receptor (ADMR), it serves as a vascular endothelium tracer for single-photon emission-computed tomography (SPECT) imaging. The drug is designed to bind to ADMRs, which are highly expressed in the pulmonary microvasculature, allowing for the visualization of abnormalities in pulmonary circulation. By assessing the functional integrity of the pulmonary endothelium, PulmoBind provides a sensitive diagnostic tool for identifying pulmonary vascular disease and monitoring disease progression, potentially offering a more sensitive alternative to traditional lung perfusion scans.
- Brand names
- PulmoBind
- Other names
- Technetium Tc 99m DFH-12
02
Targets
CALCRL (Adrenomedullin Receptor)
Beyond the preview
Go deeper on PulmoBind.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PulmoBind.